There is still scarce data about the signaling pathways and especially the physiological role of erythrocyte necroptosis
With newer molecules targeting multiple pathways (GLP-1, GIP, glucagon, amylin, insulin), the scope is expanding well beyond diabetes and weight management, towards cardiometabolic health, neurodegenerative disorders, and even oncology
Stopping the medication usually fixes the problem [26]
Semaglutide generally demonstrates a higher efficacy in reducing blood glucose and body weight compared to Liraglutide, which can be a deciding factor in its prescription
MC1R activation regulates eumelanin production, influencing pigmentation and photoprotective responses
Artificially high prices of GLP-1 medications in the U.S